2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of
Today saw the debut of a partnership between the UK NHS and an organisation that provides accreditation for clinical research professionals, aiming to attract, develop, an
Biogen has announced another big round of layoffs and cost-cutting, with 1,000 more workers set to lose their jobs after it shed around 900 last year and shelved various R
The US Centres for Disease Control Prevention (CDC) has said it would like to identify a digital health app that it could offer to its more than 10,000 employees to help s
Verily's new chief executive Stephen Gillett has lost little time in making his mark on the company, announcing a cull of 15% of its workforce and a new strategy just over a week after taki
A court in Germany has suspended a trial discussing litigation brought against BioNTech and Pfizer by CureVac alleging patent infringement in connection with their mRNA-ba
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho